|
CapitalBio™ DNA microarray
|
Conventional drug susceptibility testing
| | | | | | | |
|---|
|
No.susceptible (%)
|
No.resistant (%)
|
Total No.
|
Sensitivity (%)
|
Specificity (%)
|
AR
|
PPV (%)
|
NPV (%)
|
Kappa
|
|---|
|
Rifampin
| | | |
83.1
|
98.7
|
93.9
|
96.6
|
92.9
|
0.85
|
|
Susceptible
|
458 (98.7)
|
35 (16.9)
|
493
| | | | | | |
|
Resistant
|
6(1.3)
|
172 (83.1)
|
178
| | | | | | |
|
Total
|
464
|
207
|
671
| | | | | | |
|
Isoniazid
| | | |
79.9
|
99.6
|
93.1
|
98.8
|
91.1
|
0.84
|
|
Susceptible
|
450 (99.3)
|
44 (20.5)
|
494
| | | | | | |
|
Resistant
|
2 (0.7)
|
175 (79.5)
|
177
| | | | | | |
|
Total
|
452
|
219
|
671
| | | | | | |
- Abbreviations: PPV positive predictive value, NPV negative predictive value, AR agreement rate
